Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct
- PMID: 23163606
- DOI: 10.1111/his.12016
Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct
Abstract
Aims: Intraductal papillary neoplasm of the bile duct (IPNB) usually has a favourable prognosis, but occasionally is associated with invasive carcinoma. Overexpression of the polycomb group protein enhancer of zeste homolog 2 (EZH2) is involved in the progression of malignant tumours. In this study, we examined the significance of EZH2 expression in IPNB and its association with clinicopathological features and the expression of p16(INK4a) , p53 and mucin core proteins.
Methods and results: We examined immunohistochemically the expression of EZH2, p16(INK4a) , MUC mucin core proteins and p53 in 15 patients with IPNB without invasion, including the cystic variant [male/female ratio (M/F) = 9/6], and in 19 with IPNB associated with invasive carcinoma (M/F = 13/6). The expression levels of EZH2, p53 and MUC1 were significantly lower (P < 0.01), and of MUC6 were significantly higher (P < 0.05), in IPNB without invasion than in IPNB with invasion. Expression of EZH2 was significantly correlated with expression of MUC1 (P < 0.01) and inversely correlated with expression of MUC6 (P < 0.05). In cholangiocarcinoma cells (HuCTT-1 and TFK-1), knockdown of EZH2 and MUC1 by small interfering RNA decreased invasion and proliferation, whereas knockdown of MUC6 increased invasion.
Conclusions: Overexpression of EZH2 may be associated with malignant behaviour in IPNB in parallel with up-regulated MUC1 expression and down-regulated MUC6 expression.
© 2012 Blackwell Publishing Ltd.
Similar articles
-
Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is a marker that predicts presence of invasion in papillary biliary tumors.Hum Pathol. 2017 Apr;62:152-159. doi: 10.1016/j.humpath.2016.12.028. Epub 2017 Jan 13. Hum Pathol. 2017. PMID: 28089541
-
Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.Am J Surg Pathol. 2014 Mar;38(3):364-9. doi: 10.1097/PAS.0000000000000125. Am J Surg Pathol. 2014. PMID: 24487593
-
Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.Ann Surg Oncol. 2013 Dec;20 Suppl 3:S667-75. doi: 10.1245/s10434-013-3135-y. Epub 2013 Jul 26. Ann Surg Oncol. 2013. PMID: 23887863
-
Tumorigenesis and phenotypic characteristics of mucin-producing bile duct tumors: an immunohistochemical approach.J Hepatobiliary Pancreat Sci. 2010 May;17(3):211-22. doi: 10.1007/s00534-009-0158-7. Epub 2009 Aug 14. J Hepatobiliary Pancreat Sci. 2010. PMID: 19680592 Review.
-
A statement by the Japan-Korea expert pathologists for future clinicopathological and molecular analyses toward consensus building of intraductal papillary neoplasm of the bile duct through several opinions at the present stage.J Hepatobiliary Pancreat Sci. 2018 Mar;25(3):181-187. doi: 10.1002/jhbp.532. Epub 2018 Feb 12. J Hepatobiliary Pancreat Sci. 2018. PMID: 29272078 Review.
Cited by
-
GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct.PLoS One. 2013 Dec 2;8(12):e81706. doi: 10.1371/journal.pone.0081706. eCollection 2013. PLoS One. 2013. PMID: 24312577 Free PMC article.
-
Intraductal Papillary Neoplasm of Bile Duct: Updated Clinicopathological Characteristics and Molecular and Genetic Alterations.J Clin Med. 2020 Dec 9;9(12):3991. doi: 10.3390/jcm9123991. J Clin Med. 2020. PMID: 33317146 Free PMC article. Review.
-
An immunohistochemical panel of insulin-like growth factor II mRNA-binding protein 3 (IMP3), enhancer of zeste homolog 2 (EZH2), and p53 is useful for a diagnosis in bile duct biopsy.Virchows Arch. 2021 Oct;479(4):697-703. doi: 10.1007/s00428-021-03132-3. Epub 2021 Jun 11. Virchows Arch. 2021. PMID: 34115196
-
EZH2 Promotes Cholangiocarcinoma Development and Progression through Histone Methylation and microRNA-Mediated Down-Regulation of Tumor Suppressor Genes.Am J Pathol. 2022 Dec;192(12):1712-1724. doi: 10.1016/j.ajpath.2022.08.008. Am J Pathol. 2022. PMID: 36456043 Free PMC article.
-
CK20 and lymph node involvement predict adverse outcome of malignant intraductal papillary neoplasm of the bile duct.Histol Histopathol. 2020 May;35(5):449-456. doi: 10.14670/HH-18-179. Epub 2019 Oct 28. Histol Histopathol. 2020. PMID: 31657857
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous